Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.
Actively Recruiting
Healthy Volunteer
Researchers are conducting an observational registry to collect standardized data from adult patients receiving routine oncology care at participating cancer centers. The study aims to gather detailed information such as baseline patient characteristics, treatments administered, and outcomes to support research and improve clinical trial participation. Patient surveys are also included to enrich the data collected. No treatments or interventions are given as part of this registry. Instead, data is gathered from patients receiving their usual cancer care. This open-ended registry will continuously collect and analyze information over time to better understand treatment patterns, safety, and effectiveness. Participants will provide informed consent and contribute data through their regular care visits and surveys. Researchers will monitor treatment effectiveness mainly by tracking the time until treatment discontinuation. The registry will regularly analyze and present the data collected. Participation may last as long as the patient is receiving treatment and contributing data, with long-term follow-up possible.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the combination of KarXT and KarX-EC for cognitive impairment in people with mild to moderate Alzheimers Disease. This phase 3, randomized, double-blind, placebo-controlled study aims to understand how these treatments impact cognitive function and overall condition in this patient group. Participants will be randomly assigned to receive either KarXT plus KarX-EC or a placebo, with specified doses given on specific days. The treatment period lasts 24 weeks, during which participants will be monitored closely to assess changes in cognition and daily functioning. Throughout the 24 weeks, participants will undergo evaluations including cognitive tests like the Alzheimers Disease Assessment Scale-Cognitive Subscale 11 and the Clinicians Interview-Based Impression plus Caregiver Input. Researchers will also track safety through monitoring adverse events, vital signs, lab tests, and other clinical assessments to understand the treatments impact and safety profile.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of standard chemotherapy combined with bevacizumab, with or without the addition of INCA33890, for the first-line treatment of adults with metastatic microsatellite stable colorectal cancer who have not received prior systemic treatment for metastatic disease. This phase 3 randomized, double-blind study aims to compare these treatment approaches to better understand their impact on disease progression. Participants will receive either INCA33890 or a placebo in combination with bevacizumab and FOLFOX chemotherapy at doses defined by the study protocol. The treatments are given as part of a randomized, parallel group design where neither the participants nor the investigators know which treatment is assigned. This study will assess outcomes over several years, with primary evaluation focused on progression-free survival for up to 3 years. Throughout the study, participants will be monitored regularly for treatment response, survival, and safety through various assessments including laboratory tests and quality of life questionnaires. Researchers will measure overall survival, objective response rate, duration of response, and treatment-related adverse events for up to 4 years. Quality of life changes will also be tracked using validated questionnaires. The total duration of participation may extend up to around 4 years, with ongoing safety and efficacy evaluations.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Edwards SAPIEN X4 and X4S Transcatheter Heart Valves in people with severe, symptomatic calcific aortic stenosis. This is a prospective, single-arm, multicenter study that includes a separate registry for subjects with bicuspid aortic valve morphology. The study aims to provide important data on these balloon-expandable bioprosthetic valves in this patient population. Participants will undergo a transcatheter aortic valve replacement TAVR procedure using either the SAPIEN X4 or SAPIEN X4S valve. Those with bicuspid aortic valves will be enrolled in a separate registry and also undergo TAVR. The study involves implantation of the valve device via catheter, with no randomization or comparison groups. The primary study period extends up to one year after the procedure. During the study, participants will be monitored through regular assessments including evaluation of survival and stroke occurrence at one year. Secondary outcomes include quality of life measured by the Kansas City Cardiomyopathy Questionnaire, paravalvular leak assessment at 30 days, and new permanent pacemaker implantation also at 30 days. Edwards Lifesciences sponsors the study, and participants will be followed until study completion in 2037 to monitor safety and effectiveness outcomes.
Actively Recruiting
Researchers are studying patients with advanced or metastatic non-small cell lung cancer NSCLC to create control groups using current and future patient data. The study aims to generate precision external control arms by observing different patient cohorts categorized by specific genetic mutations and treatment lines. This observational study helps understand treatment responses in real-world settings without assigning specific therapies. Participants are grouped based on their treatment regimens and genetic profiles, such as those starting first-line immune checkpoint inhibitor therapies, patients with actionable EGFR mutations, KRAS mutations, or varying PD-L1 expression levels. The study observes patients receiving standard therapies, such as platinum doublets, targeted agents like osimertinib or lazertinib, or other recommended treatments across different lines of therapy. The study spans from January 2026 to April 2029. During the study, participants response rates to therapies will be assessed, focusing on Objective Response Rate ORR in metastatic NSCLC patients treated in second or third line settings. Secondary measures include progression-free survival, overall survival, and time to next treatment. Participants will be monitored through clinical evaluations and imaging studies to track disease status. This study involves no investigational treatments and aims to gather data from real-world clinical practice over several years.
Actively Recruiting
Researchers are evaluating the efficacy and safety of lutetium 177Lu vipivotide tetraxetan AAA617 in adult male participants with oligometastatic prostate cancer OMPC that is progressing after definitive treatment to the primary tumor. The study aims to delay progression to fatal metastatic disease and preserve quality of life by postponing androgen deprivation therapy ADT. This is a Phase III, open-label, randomized trial involving participants with PSMA-positive OMPC. Participants will undergo baseline disease assessments including PETCT scans using gallium 68Ga gozetotide or piflufolastat 18F, along with CTMRI and bone scans. All will receive Stereotactic Body Radiation Therapy SBRT to metastatic lesions over about three weeks. Those in the investigational group will then receive up to four cycles of AAA617 infusions every six weeks. Participants in the control group will be observed after SBRT without additional treatment. Visits occur weekly during cycles and every 16 weeks thereafter until disease progression. During the study, participants will be monitored through regular imaging and clinical assessments to track disease progression and side effects. Outcome measures include metastasis-free survival, time to hormonal therapy, PSA progression, quality of life questionnaires, and safety events, with follow-up lasting approximately 7.5 years. This comprehensive monitoring seeks to understand the treatments impact on delaying progression and maintaining patient well-being over time.
Actively Recruiting
Researchers are evaluating whether ataciguat can slow the progression of moderate calcific aortic valve stenosis CAVS in adults aged 50 and older. This study is conducted in two parts Part A focuses on whether ataciguat reduces calcium buildup in the aortic valve over 24 weeks, while Part B examines if the drug slows narrowing of the valve area and improves peak oxygen consumption over 48 weeks. Safety, tolerability, and how the body processes ataciguat are also assessed. Participants receive either ataciguat or a placebo daily for up to 156 weeks. Part A enrolls about 132 participants, and Part B will begin after Part A completes, enrolling around 1144 participants. Part B includes additional evaluation of heart function and ability to exercise. The study uses a randomized, double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants undergo imaging tests like CT scans and echocardiograms to measure valve calcium and valve area. Cardiopulmonary exercise testing CPET is used to assess peak oxygen consumption. Researchers also monitor heart function, symptoms, and quality of life using questionnaires. Assessments occur mainly at baseline, Week 24, and Week 48, with long-term follow-up to 156 weeks for safety and efficacy. The studys total duration extends to 2030.
Actively Recruiting
This research evaluates the use of the Aortix System, a circulatory support device, compared to usual medical care in patients hospitalized with acute decompensated heart failure ADHF who have persistent congestion despite standard treatment and are resistant to diuretics. The study includes patients irrespective of their hearts ejection fraction and aims to assess safety and effectiveness in this population. Participants will be randomly assigned in a 21 ratio to either receive the Aortix device or continue with standard medical therapy following a specific diuretic care algorithm. There is also a registry group enrolling patients indicated for advanced therapies like heart transplant or LVAD, who will all receive the Aortix device. The study plans to enroll up to 320 subjects across about 55 sites. During the study, participants will be monitored for major adverse events related to the device and procedure within 30 days. Researchers will measure fluid loss, rehospitalization rates, mortality, kidney function, and patient symptom assessments. The study includes baseline and follow-up evaluations up to 30 days post treatment to understand both safety and effectiveness outcomes.
Actively Recruiting
This research evaluates the safety and effectiveness of the GORE4 CARDIOFORM Septal Occluder device in adults who have had an ischemic stroke thought to be caused by a patent foramen ovale PFO, a heart condition. The study aims to assess device performance and the quality of operator training in real-world, post-approval settings. Up to 636 adults aged 18 to 70 will participate across up to 40 U.S. centers. Participants will receive the GORE4 CARDIOFORM Septal Occluder to close the PFO, combined with antiplatelet medical management. The device is commercially available and implanted as a one-time procedure. After implantation, participants will be followed for up to 5 years with scheduled visits at 1 month, 6 months, 12 months, and annually thereafter. Throughout the study, participants will undergo assessments including echocardiographic examinations to evaluate PFO closure and residual shunts, monitoring for new atrial arrhythmias, and tracking serious adverse events related to the device or procedure. The main outcomes include measuring the proportion of participants experiencing recurrent ischemic stroke up to 24 months after implantation and safety events within 30 days. This long-term follow-up allows careful evaluation of device performance and participant health over time.
1-10 of 18
1